EULAR/ACR Provisional Classification
Criteria for Polymyalgia Rheumatica
Members of the Development Group

Christian Dejaco, Department of Rheumatology, Medical University Graz, Graz, Austria
Christina Duftner, Department of Internal Medicine, General Hospital of the Elisabethinen, Klagenfurt, Austria
Michael Schirmer, Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria
Hanne Slott Jensen, Gentofte Hospital, Rheumatology Division, Hellerup, Denmark
Pierre Duhaut, Service de Médecine Interne, Amiens, France
Wolfgang A. Schmidt, Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Germany
Gyula Poór, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
Novák Pál Kaposi, Radiology Department, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
Peter Mandl, General and Pediatric Rheumatology Department, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
Peter V. Balint, General and Pediatric Rheumatology Department, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
Zsuzsa Schmidt, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
Annamaria Iagnocco, Rheumatology Unit, Clinica e Terapia Medica Department, Sapienza Università di Roma, Rome, Italy
Carlo Salvarani, Department of Rheumatology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
Carlotta Nannini, Rheumatology Unit, Ospedale Misericordia e Dolce, Prato, Italy
Fabrizio Cantini, Rheumatology Unit, Ospedale Misericordia e Dolce, Prato, Italy
Pierluigi Macchioni, Department of Rheumatology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
Marco Cimmino, Dept. of Internal Medicine, University of Genoa, Genoa, Italy
Nicolò Pipitone, Department of Rheumatology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
Artur Bąchta, Dept. of Internal Medicine and Rheumatology, WIM CSK MON, Warsaw, Poland
Georgina Espígol-Frigolé, Center for Diagnosis Imaging, Hospital Clínic, Montserrat del Amo, Barcelona, Spain
Members of the Development Group

Maria Cid, Dept. of Internal Medicine, Hospital Clinic Provincial, Barcelona, Spain
Víctor M. Martínez-Taboada, Servicio de Reumatología, Universidad de Cantabria, Santander, Spain
Elisabeth Nordborg, Sahlgren University Hospital, Department of Rheumatology, Göteborg, Sweden
Haner Direskenel, Department of Rheumatology, Marmara University Medical School, Istanbul, Turkey
Sibel Zehra Aydin, Department of Rheumatology, Marmara University Medical School, Istanbul, Turkey
Kkalid Ahmed, Department of Rheumatology, Princess Alexandra Hospital, Harlow, United Kingdom
Bhaskar Dasgupta, Department of Rheumatology, Southend University Hospital, Essex, United Kingdom
Brian Hazelman, Department of Rheumatology, Cambridge University, Cambridge, United Kingdom
Colin Pease, Rheumatology and Rehabilitation Research Unit, University of Leeds, Leeds, United Kingdom
Raashid Luqmani, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Oxford, United Kingdom
Richard J. Wakefield, Rheumatology and Rehabilitation Research Unit, University of Leeds, Leeds, United Kingdom
Andy Abril, Division of Rheumatology, Mayo Clinic College of Medicine, Jacksonville Florida, USA
Clement J. Michet, Department of Internal medicine, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
Cynthia S. Crowson, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
Eric L. Matteson, Division of Rheumatology and Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
Hilal Maradit Kremers, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
Kenneth T. Calamia, Division of Rheumatology, Mayo Clinic College of Medicine, Jacksonville, Florida USA
Ralph Marcus, Rheumatology Associates of North Jersey, Teaneck, New Jersey, USA
Mehrdad Maz, Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Scottsdale, Arizona, USA
Neil J. Gonter, Rheumatology Associates of North Jersey, Teaneck, New Jersey, USA
Rickey E. Carter, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
Funding

• EULAR
• ACR
• Mayo Clinic
• Biobanque de Picardie
• In-kind donations of time, effort and expense by each of the investigators and their staffs
Background

- PMR is the most common inflammatory rheumatic disease of the elderly.

- Accurate diagnosis is difficult in PMR because proximal pain and stiffness syndrome, a commonly accepted phenotype of PMR, can occur in many other rheumatologic and inflammatory illnesses.

- Lack of standardized classification criteria has been a major factor hampering development of rational therapeutic approaches to management of PMR.
General Approach to PMR

- Presenting complaint
  - Articular/periarticular non-articular
    - Clinical features
      - Age >50 years, predominant shoulder and thigh symptoms
        - Symmetrical
        - Predominant peripheral joint symptoms, radiographs
        - Peripheral hand/foot oedema
        - Multisystem disease autoantibodies
        - Weakness of muscles, high creatine kinase
    - Diagnosis
      - Polymyalgia rheumatica
      - RA, other inflammatory arthritis
      - RS3PE syndrome
      - SLE, vasculitis
        - Other collagen vascular diseases
        - Inflammatory myopathy
  - Inflammatory
    - Morning stiffness
    - Joint swelling
    - Proximal pain or stiffness
      - Articular
        - Shoulder acromioclavicular joints, cervical spine, hips radiographs
      - Periarticular
        - Capsular restriction etc
        - Ultrasonography
        - Elevated sedimentation rate, C-reactive protein
        - Relevant history and tests eg urinalysis
        - Microscopic haematuria
        - Fever, murmur
        - Bacterial endocarditis
          - Weight loss, associated features
          - Tender spots, longstanding history
          - TSH, bone profile (PTH, vitamin D)
          - Rigidity, shuffle, stare, gradual onset
    - Adhesive capsulitis
    - Rotator cuff lesions
    - Concomitant sepsis eg urinary infection
    - Occult and deep sepsis (hip, muscle and body cavity abscesses, osteomyelitis etc)
  - Non-inflammatory/Infective/neoplastic
    - Neuro/endocrine
      - Neoplasia eg myeloma
      - Fibromyalgia, chronic pain syndromes, depression
      - Endocrinopathy
      - Metabolic bone disease
      - Parkinsonism

© 2012 ACR / EULAR
Classification Criteria for PMR are Needed for Major Reasons

• To classify this clinical syndrome as a distinct disease entity

• To compare like groups of patients across populations of patients seen in different countries

• To facilitate prediction of disease- and treatment-related outcomes

• To develop management guidelines across different treatment settings
Objective

To develop EULAR/ACR classification criteria for PMR by assessing the performance of candidate criteria in a prospective longitudinal study of patients presenting with new onset bilateral shoulder pain.
Methods

• **Candidate inclusion/exclusion criteria** for classification of PMR were defined through a consensus conference and a wider Delphi survey.

• **International prospective study** (21 centers in 10 countries) to evaluate the utility of candidate criteria for PMR in patients presenting with the polymyalgia syndrome.

• **Study population**: 125 subjects with PMR and 169 comparison subjects with conditions mimicking PMR (49 RA, 29 new-onset seronegative arthritis or connective tissue disease, 52 shoulder conditions, 39 other).

• **Follow-up**: Baseline, weeks 1, 4, 12 and 26.

• **Statistical analyses**: chi-square and rank sum tests, logistic regression models, concordance c statistic, factor analyses, classification trees, gradient boosting regression tree models.
Study Design

New-onset PMR cases

Potential control subjects

Baseline 1 week 4 weeks 12 weeks 26 weeks

Measurements
• Demographics
• Vital signs
• Weight, height
• Family history
• Clinical history
• Labs
• Steroid therapy
• Physician&patient-based measures
• Ultrasound

PMR cases

~15-17%

~10%

Non-PMR controls

Measurements
• Labs
• Steroid therapy
• Physician&patient-based measures

Measurements
• Labs
• Steroid therapy
• Physician&patient-based measures

Measurements
• Labs
• Steroid therapy
• Physician&patient-based measures

Measurements
• Labs
• Steroid therapy
• Physician&patient-based measures
• Ultrasound
## Univariate Logistic Regression Models to Distinguish PMR Subjects from Comparison Subjects

<table>
<thead>
<tr>
<th>Variable</th>
<th>PMR vs. All Comparison Subjects</th>
<th>PMR vs. RA</th>
<th>PMR vs. Shoulder Conditions*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of symptoms ≥2 weeks</td>
<td>1.1 (0.3, 4.0)</td>
<td>0.50</td>
<td>1.3 (0.2, 7.3)</td>
</tr>
<tr>
<td>Shoulder pain or limited range of motion</td>
<td>2.1 (0.7, 6.8)</td>
<td>0.52</td>
<td>1.3 (0.2, 7.3)</td>
</tr>
<tr>
<td>Shoulder tenderness</td>
<td>1.1 (0.7, 1.9)</td>
<td>0.51</td>
<td>0.7 (0.3, 1.7)</td>
</tr>
<tr>
<td>Hip pain or limited range of motion</td>
<td>2.5 (1.5, 3.9)</td>
<td>0.61</td>
<td>3.0 (1.5, 6.0)</td>
</tr>
<tr>
<td>Hip tenderness</td>
<td>2.3 (1.4, 3.8)</td>
<td>0.60</td>
<td>2.8 (1.3, 5.8)</td>
</tr>
<tr>
<td>Neck aching</td>
<td>1.1 (0.7, 1.8)</td>
<td>0.51</td>
<td>0.9 (0.5, 1.8)</td>
</tr>
<tr>
<td>Morning stiffness &gt;45 minutes</td>
<td>4.5 (2.6, 7.7)</td>
<td>0.67</td>
<td>1.5 (0.7, 3.3)</td>
</tr>
<tr>
<td>Weight loss &gt; 2kg</td>
<td>1.8 (1.1, 3.0)</td>
<td>0.56</td>
<td>1.2 (0.6, 2.4)</td>
</tr>
<tr>
<td>Carpal tunnel syndrome</td>
<td>1.0 (0.5, 1.8)</td>
<td>0.50</td>
<td>0.6 (0.3, 1.5)</td>
</tr>
<tr>
<td>Peripheral synovitis</td>
<td>0.7 (0.5, 1.2)</td>
<td>0.54</td>
<td>0.1 (0.08, 0.3)</td>
</tr>
<tr>
<td>Other joint pain</td>
<td>0.5 (0.3, 0.9)</td>
<td>0.57</td>
<td>0.2 (0.1, 0.4)</td>
</tr>
<tr>
<td>Abnormal ESR or CRP</td>
<td>13.8 (5.3, 36)</td>
<td>0.67</td>
<td>4.0 (1.2, 13)</td>
</tr>
<tr>
<td>Abnormal RF or ACPA</td>
<td>0.4 (0.2, 0.7)</td>
<td>0.57</td>
<td>0.2 (0.07, 0.4)</td>
</tr>
<tr>
<td>Abnormal serum protein electrophoresis</td>
<td>2.0 (1.1, 3.6)</td>
<td>0.58</td>
<td>1.9 (0.8, 4.8)</td>
</tr>
<tr>
<td>MHAQ (per 1 unit increase)</td>
<td>2.3 (1.6, 3.4)</td>
<td>0.66</td>
<td>1.3 (0.7, 2.2)</td>
</tr>
</tbody>
</table>
Univariate Logistic Regression Models to Distinguish PMR Subjects from Comparison Subjects

• Criteria items related to hip involvement have significant ability to discriminate PMR from all comparison subjects.

• Early morning stiffness, Modified Health Assessment Questionnaire (MHAQ), weight loss, and raised laboratory markers distinguish PMR from comparison subjects, particularly those with shoulder conditions.

• Presence of ACPA or RF, peripheral synovitis and joint pains have significant ability to distinguish PMR from RA.

• Shoulder pain and abnormal ESR/CRP were defined as required criteria in the scoring algorithm for PMR.
### Multivariable Logistic Regression Models

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Model based on factors</th>
<th>Model based on factors w/o shoulder tenderness plus abnormal RF/ACPA</th>
<th>Model based on factors plus abnormal RF/ACPA and MHAQ</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>p</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>Pain/ limited hip range of motion</td>
<td>2.7 (1.5, 4.8)</td>
<td>0.001</td>
<td>2.1 (1.1, 4.0)</td>
</tr>
<tr>
<td>Other joint pain</td>
<td>0.4 (0.2, 0.6)</td>
<td>&lt;0.001</td>
<td>0.4 (0.2, 0.7)</td>
</tr>
<tr>
<td>Morning stiffness &gt; 45 min</td>
<td>5.2 (2.9, 9.4)</td>
<td>&lt;0.001</td>
<td>6.2 (3.2, 11.8)</td>
</tr>
<tr>
<td>Shoulder tenderness</td>
<td>0.9 (0.5, 1.8)</td>
<td>0.80</td>
<td></td>
</tr>
<tr>
<td>Abnormal RF/ACPA</td>
<td></td>
<td></td>
<td>0.3 (0.1, 0.8)</td>
</tr>
<tr>
<td>MHAQ, per 1 unit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Likelihood ratio test for additional terms</td>
<td>P&lt;0.001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Three multivariable models were considered. The second model shown in the table above (with hip pain, other joint pain, morning stiffness, and abnormal RF/ACPA) was the best multivariate logistic regression model.
Scoring Algorithm without Ultrasound – 3 required criteria: age ≥50 years, bilateral shoulder aching, abnormal ESR/CRP

<table>
<thead>
<tr>
<th>Optional classification criteria</th>
<th>OR (95% CI)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morning stiffness &gt; 45 minutes</td>
<td>6.2 (3.2, 11.8)</td>
<td>2</td>
</tr>
<tr>
<td>Hip pain or limited range of motion</td>
<td>2.1 (1.1, 4.0)</td>
<td>1</td>
</tr>
<tr>
<td>Normal RF or ACPA</td>
<td>3.0 (1.3, 6.8)</td>
<td>2</td>
</tr>
<tr>
<td>Absence of other joint pain</td>
<td>2.7 (1.4, 5.0)</td>
<td>1</td>
</tr>
</tbody>
</table>

• **Optimal cut-off point = 4**
• A score of 4 had 72% sensitivity and 65% specificity for discriminating all comparison subjects from PMR.
• The specificity was higher (79%) for discriminating shoulder conditions from PMR and lower (61%) for discriminating RA from PMR.
• The c-statistic for the scoring algorithm was 75%.
• A total of 34 (28%) PMR cases and 59 (35%) of comparison subjects were incorrectly classified.
Scoring Algorithm with Ultrasound – 3 required criteria: age ≥50 years, bilateral shoulder aching, abnormal ESR/CRP

<table>
<thead>
<tr>
<th>Optional classification criteria</th>
<th>OR (95% CI)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morning stiffness &gt;45 minutes</td>
<td>5.0 (2.8, 9.1)</td>
<td>2</td>
</tr>
<tr>
<td>Hip pain, limited range of motion</td>
<td>1.4 (0.8, 2.6)</td>
<td>1</td>
</tr>
<tr>
<td>Normal RF or ACPA</td>
<td>5.2 (2.1, 12.6)</td>
<td>2</td>
</tr>
<tr>
<td>Absence of other joint pain</td>
<td>2.2 (1.3, 4.0)</td>
<td>1</td>
</tr>
</tbody>
</table>

**ULTRASOUND CRITERIA**

At least 1 shoulder with subdeltoid bursitis and/or biceps tenosynovitis and/or glenohumeral synovitis AND at least 1 hip with synovitis and/or trochanteric bursitis

<table>
<thead>
<tr>
<th>ULTRASOUND CRITERIA</th>
<th>OR (95% CI)</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least 1 shoulder with subdeltoid bursitis and/or biceps tenosynovitis and/or glenohumeral synovitis AND at least 1 hip with synovitis and/or trochanteric bursitis</td>
<td>2.6 (1.3, 5.3)</td>
<td>1</td>
</tr>
<tr>
<td>Both shoulders with subdeltoid bursitis, biceps tenosynovitis or glenohumeral synovitis</td>
<td>2.1 (1.2, 3.7)</td>
<td>1</td>
</tr>
</tbody>
</table>

Optimal cut-off point = 5
- A score 5 had 71% sensitivity and 70% specificity for discriminating all comparison subjects from PMR.
- The specificity was higher (86%) for discriminating shoulder conditions from PMR and lower (65%) for discriminating RA from PMR.
- The c-statistic for the scoring algorithm was 78%.
- A total of 32 (29%) PMR cases and 47 (30%) of comparison subjects were incorrectly classified.
Conclusions

- Patients >50 years old presenting with new bilateral shoulder pain (not better explained by an alternative diagnosis) and elevated CRP/ESR can be classified as having PMR in the presence of morning stiffness >45 min, and new hip involvement in the absence of peripheral synovitis or positive RA serology.

- Ultrasound findings of bilateral shoulder abnormalities or abnormalities in one shoulder and hip may significantly improve both sensitivity and specificity of the clinical criteria.

- Determining the utility of the criteria will require clinic-based studies in the primary and specialty care settings.

- Development of better disease biomarkers is needed for diagnosis and activity assessment in PMR.
Blinded Multi-rater Evaluation of Diagnosis and Candidate Classification Criteria for Polymyalgia Rheumatica
Background

• Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease of the elderly, and there is considerable uncertainty in diagnosis of PMR.

• Following a large international study for classification of PMR, the investigators performed a formal diagnostic re-evaluation of candidate classification criteria.
Objective

To assess multi-rater discrimination of polymyalgia rheumatica (PMR) from other conditions mimicking PMR
Methods

• 23 investigators blindly rated 30 patient profiles (10 PMR cases and 20 controls)

• Data provided: clinical features, examination findings (i.e., restricted shoulder/hip movement, synovitis), inflammatory markers, RF, anti-CCP serology and steroid response

• Each criteria was rated on a 5-point scale reflecting the degree of confidence of a PMR diagnosis
  – 1=strongly influences diagnosis of PMR
  – 5=strongly influences the diagnosis was not PMR
  – See weighting scale
Methods

• Investigators were asked to provide a diagnosis of PMR or other condition and indicate whether they would enter such a subject in a clinical trial.

• A mean rating across all raters was taken in order to assess the diagnostic accuracy of each candidate criteria.

• A composite score was used to determine the areas under the ROC curve (AUC) and c-statistic.

• Patients were categorized into 3 groups based on raters' misclassification rates.
  – Group 1: greater than 50% misclassified
  – Group 2: 20%- 50% misclassified
  – Group 3: less than 20% misclassified
Results

- Misclassification proportion was high in 10 of the 30 patients.

- **Group 1: >50% misclassified** (n=3, 1 case, 2 control subjects) – Factors that contributed to the misclassification were normal (either ESR and/or CRP), poor or ill-sustained corticosteroid response and RF positivity without peripheral synovitis.

- **Group 2: 20-50% misclassified** (n=7, 4 cases, 3 controls) – Misclassification was related to persistent synovitis, lack of complete/sustained corticosteroid response, RF or CCP positivity and low baseline ESR and/or CRP.

- The AUC c-statistic suggested that gender, duration of symptoms, systemic symptoms such as weight loss, neck pain, limitation of movement and serum electrophoresis were unhelpful to the blinded rater, in discriminating cases from controls (c-statistic < 0.8 in all).

- Bilateral hip pain, morning stiffness, ESR and CRP levels (pre- and especially post-CS), and corticosteroid response were good discriminators of cases from controls (c-statistic > 0.8 in all; see Table in next slide).
Conclusions

• A significant proportion of cases/controls are difficult to classify.

• A stepped diagnostic process and most candidate criteria items perform well in discriminating PMR cases from controls.

• Questions that require further investigation:
  – Does PMR always adequately respond to steroids?
  – Can polymyalgic RF-positive disease without peripheral synovitis occur?
Patient-reported Outcome Measures in Patients with Polymyalgia Rheumatica:

Results from an international, prospective, multi-center study
Background

• There is considerable uncertainty in classification and continued evaluation of patients with PMR.

• PMR may have a heterogeneous disease course.

• Patient-reported outcome measures are routinely used in clinical practice and research studies of patients with rheumatic diseases.

• The value of patient-reported outcome measures for outcome assessment in PMR is unknown.

• It is also unknown whether patient-reported outcome measures in PMR correlate with steroid response and inflammatory markers.
Objective

To evaluate the disease course and performance of patient-reported outcome measures in patients with PMR
Methods

• **Study population:** 112 patients with new onset PMR

• **Corticosteroid treatment:** Prednisolone/ prednisone dose of 15 mg daily and tapered gradually over 26 weeks

• **Follow-up:** Clinical and questionnaire-based assessments at baseline and weeks 1, 4, 12 and 26 following start of steroid therapy

• **Measurements:** Personal and family history, clinical signs and symptoms, laboratory results, treatment details, ultrasound evaluation of shoulders and hip, disability (MHAQ), quality of life (SF36), and patient-reported outcomes (PRO) of global pain, PMR pain, shoulder pain and fatigue obtained using visual analogue scales (VAS)

• **Statistical analysis:** Spearman methods were used to assess correlations between improvement measures
Results

• **Initial presentation:** 99% patients had shoulder pain and 71% had hip pain. Median duration of morning stiffness was 120 minutes with median global pain VAS 60.5, median MHAQ 1.1, fatigue VAS 60. 98% patients had abnormal CRP or ESR.

• **Δ at 4 weeks:** All PRO parameters improved dramatically (70% improvement) in the majority of the patients. 71% of patients for global VAS, 74% for PMR VAS and 56% for fatigue VAS. 64% of patients had normal CRP/ESR values at 4 weeks.

• **MHAQ:** Median change in MHAQ from baseline to 4 weeks was -0.875. Median change from baseline to 26 weeks was -1.0. The sections of MHAQ that are particularly influenced by early morning stiffness such as rising, dressing, reaching showed very significant change (p<0.001) with treatment.
Results

- **SF 36 PCS**: The physical QOL as measured by physical component score (PCS) of the SF-36 showed severe impairment at baseline (35). This was lower than values typically seen in other rheumatic diseases such as RA. PCS showed a dramatic improvement with corticosteroid therapy, reaching 41 at 4 weeks and 48 at 12 weeks.

- **SF 36 MCS**: The mental component score (MCS) did not show any impairment at baseline and remained relatively stable throughout follow-up.
## Clinical and Patient-Reported Outcomes in Patients with PMR

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Shoulder pain</td>
<td>111 (99)</td>
<td>63 (61)</td>
<td>39 (36)</td>
<td>31 (29)</td>
<td>24 (23)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hip pain</td>
<td>79 (71)</td>
<td>26 (25)</td>
<td>15 (14)</td>
<td>8 (8)</td>
<td>11 (10)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Global pain VAS, median (IQR)</td>
<td>60.5 (47, 80)</td>
<td>22.5 (8.5, 45)</td>
<td>7.0 (2.0, 18.0)</td>
<td>4.0 (1.0, 13.0)</td>
<td>5.0 (1.0, 19.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Morning stiffness duration (min), median (IQR)</td>
<td>120 (60, 240)</td>
<td>7.5 (0, 30)</td>
<td>0 (0, 10)</td>
<td>0 (0, 0)</td>
<td>0 (0, 0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MHAQ, median (IQR)</td>
<td>1.1 (0.8, 1.6)</td>
<td>0.4 (0.1, 0.8)</td>
<td>0.1 (0, 0.4)</td>
<td>0 (0, 0.1)</td>
<td>0 (0, 0.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fatigue VAS, median (IQR)</td>
<td>60 (35, 78)</td>
<td>26 (7, 44)</td>
<td>9 (2, 30)</td>
<td>8 (1, 24)</td>
<td>4 (2, 22)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PCS SF36, median (IQR)</td>
<td>35 (31, 39)</td>
<td>41 (35, 46)</td>
<td>46 (41, 50)</td>
<td>48 (43, 51)</td>
<td>48 (41, 51)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MCS SF36, median (IQR)</td>
<td>47 (42, 53)</td>
<td>46 (41, 51)</td>
<td>48 (43, 53)</td>
<td>48 (44, 52)</td>
<td>46 (45, 53)</td>
<td>0.025</td>
</tr>
<tr>
<td>Abnormal ESR</td>
<td>94 (88)</td>
<td>42 (57)</td>
<td>25 (29)</td>
<td>28 (30)</td>
<td>21 (25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Abnormal CRP</td>
<td>98 (95)</td>
<td>26 (41)</td>
<td>17 (25)</td>
<td>21 (26)</td>
<td>14 (19)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Prednisone dosage, median (IQR)</td>
<td>15 (15, 15)</td>
<td>15 (15, 15)</td>
<td>12.5 (12.5, 12.5)</td>
<td>8.8 (7.5, 10)</td>
<td>5.0 (5, 7.5)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
Change in patient-reported outcomes and ESR/CRP over time
### Algorithm score versus steroid response in PMR: Lack of association confirms why steroid responsiveness cannot be used as criteria item

<table>
<thead>
<tr>
<th>Score</th>
<th>Did not respond</th>
<th>Responded</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 4</td>
<td>12 (32%)</td>
<td>25 (68%)</td>
</tr>
<tr>
<td>≥ 4</td>
<td>16 (27%)</td>
<td>44 (73%)</td>
</tr>
</tbody>
</table>

*Chi-square test p=0.54*

<table>
<thead>
<tr>
<th>Score</th>
<th>Did not respond</th>
<th>Responded</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3 (60%)</td>
<td>2 (40%)</td>
</tr>
<tr>
<td>2</td>
<td>3 (38%)</td>
<td>5 (62%)</td>
</tr>
<tr>
<td>3</td>
<td>6 (25%)</td>
<td>18 (75%)</td>
</tr>
<tr>
<td>4</td>
<td>6 (32%)</td>
<td>13 (68%)</td>
</tr>
<tr>
<td>5</td>
<td>7 (35%)</td>
<td>13 (65%)</td>
</tr>
<tr>
<td>6</td>
<td>3 (14%)</td>
<td>18 (86%)</td>
</tr>
</tbody>
</table>

*Spearman correlation coefficient examining the association between score by algorithm (continuous) and percent improvement (continuous) is 0.12 (p=0.24)*

### Comparison of score (<4 vs. ≥4) by algorithm and response* at 26 weeks

<table>
<thead>
<tr>
<th>Score</th>
<th>Did not respond</th>
<th>Responded</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 4</td>
<td>5 (20%)</td>
<td>20 (80%)</td>
</tr>
<tr>
<td>≥ 4</td>
<td>10 (23%)</td>
<td>34 (77%)</td>
</tr>
</tbody>
</table>

*Chi-square test p=0.79*
Conclusions

- Patient-reported outcome measures, including MHAQ, global, PMR and fatigue VAS, and inflammatory markers, perform well in assessing disease activity in PMR.

- Percent improvement in patient-reported outcome measures are highly correlated with each other, but ESR and CRP correlate less strongly.

- A minimum set of outcome measures consisting of measures of shoulder pain and function and an inflammatory marker can be used in practice and clinical trials in PMR.
Utility of Ultrasound in the Classification Assessment of Shoulder Pain in Polymyalgia Rheumatica: Results From an International, Prospective, Multi-Center Longitudinal Study
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease of the elderly. There is considerable uncertainty in classification of PMR. Musculoskeletal ultrasound has become an important tool in clinical practice in rheumatology, and has demonstrated value across a range of rheumatic conditions. The classification value of ultrasound in distinguishing PMR from other conditions mimicking PMR is unknown.
Objective

To evaluate the performance of musculoskeletal ultrasound in the initial assessment and follow up of patients aged 50 years and over presenting with recent onset bilateral shoulder pain
Methods

• Study population:
  o 120 patients with PMR
  o 154 control subjects with newly diagnosed conditions mimicking PMR including:
    – 46 RA with shoulder involvement
    – 47 non-RA shoulder conditions
    – 21 controls without shoulder pain or known shoulder condition

• Standard ultrasound protocol developed as part of a 6-month prospective study and included assessment of subdeltoid bursitis, biceps tenosynovitis, glenohumeral or hip synovitis, and trochanteric bursitis.

• A preceding training and standardization exercise of operators at different sites in the study demonstrated very good inter-center comparability of results.
## Ultrasound Findings

<table>
<thead>
<tr>
<th>Condition</th>
<th>PMR (N=120)</th>
<th>All Controls (N=154)</th>
<th>RA with Shoulder Involvement (N=46)</th>
<th>Non-RA Shoulder Condition (N=47)</th>
<th>Controls without Shoulder Conditions (N=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least ONE shoulder with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis</td>
<td>83%</td>
<td>70%**</td>
<td>78%</td>
<td>62%**</td>
<td>19%**</td>
</tr>
<tr>
<td>BOTH shoulders with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis</td>
<td>59%</td>
<td>43%**</td>
<td>65%</td>
<td>26%**</td>
<td>0%**</td>
</tr>
<tr>
<td>At least ONE shoulder with subdeltoid bursitis or biceps tenosynovitis</td>
<td>82%</td>
<td>63%**</td>
<td>72%</td>
<td>53%**</td>
<td>19%**</td>
</tr>
<tr>
<td>BOTH shoulders with subdeltoid bursitis or biceps tenosynovitis</td>
<td>57%</td>
<td>35%**</td>
<td>52%</td>
<td>21%**</td>
<td>0%**</td>
</tr>
<tr>
<td>At least ONE hip with synovitis or trochanteric bursitis</td>
<td>38%</td>
<td>23%*</td>
<td>30%</td>
<td>18%*</td>
<td>0%**</td>
</tr>
<tr>
<td>BOTH hips with synovitis or trochanteric bursitis</td>
<td>19%</td>
<td>8%**</td>
<td>9%</td>
<td>4%</td>
<td>0%*</td>
</tr>
<tr>
<td>At least ONE shoulder and ONE hip with findings as above</td>
<td>33%</td>
<td>16%**</td>
<td>17%</td>
<td>11%**</td>
<td>0%**</td>
</tr>
<tr>
<td>BOTH shoulder and BOTH hips with findings as above</td>
<td>12%</td>
<td>7%</td>
<td>6%</td>
<td>2%*</td>
<td>0%</td>
</tr>
</tbody>
</table>

*p<0.05; **p<0.01 compared to PMR
Subdeltoid bursitis
Glenohumeral joint effusion (from dorsal)
Trochanteric bursitis
Hip joint effusion
Results

• Patients with PMR were more likely to have abnormal ultrasound findings in the shoulder (particularly subdeltoid bursitis and biceps tenosynovitis), and somewhat more likely to have abnormal findings in the hips than control subjects, as a group.

• PMR could not be distinguished from RA on the basis of ultrasound, but could be distinguished from non-RA shoulder conditions and subjects without shoulder conditions.
Conclusions

• In this largest and first multicenter study of ultrasound in PMR, most subjects with PMR have abnormal findings on shoulder ultrasound.

• Ultrasound has limited value in distinguishing PMR from RA, but has value in discriminating PMR from other conditions associated with shoulder pain.

• Ultrasound of the shoulders and hips may have added value for classification as PMR.